Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 ...

NYSE:ABBV Earnings and Revenue History February 21st 2025 Zooming In On AbbVie's Earnings. As finance nerds would already ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

The DOJ backs Medicare price negotiations amidst a Novartis lawsuit, while President Trump vows to lower U.S. drug costs.

Overview of the Migraine Drugs MarketThe global Migraine Drugs Market is valued at $6.37 billion in 2024 and is projected to ...

Dorman Products’ (DORM) growth trajectory appears optimistic, driven by its expanding portfolio of aftermarket components.

WisdomTree U.S. High Dividend Fund ETF offers stability but underperforms in yield and growth. Learn why DHS lags behind ...

Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

The healthcare industry is poised for growth driven by the rapid adoption of new and advanced medical technologies to enhance diagnosis. Hence, investors might consider investing in healthcare stocks, ...

Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE:JNJ) blockbuster arthritis therapy Stelara (ustekinumab) in the U.S. weeks ...